

# MORE THAN HALF OF PATIENTS

with HPP may not have overt bone manifestations\*<sup>1</sup>



Neurological,<sup>†</sup> Pain, Fatigue,<sup>1,2</sup>  
Muscle weakness<sup>1</sup>



+ bone  
manifestations<sup>‡</sup>

Rethink HPP disease burden especially the impact on daily function and QoL, and the potential for progression in children and adults<sup>3-5</sup>

\*Skeletal manifestations were present in 44.2% (N=53/120) of paediatric (<18 years) and 48.2% (N=66/137) of adult (≥18 years) patients with HPP.<sup>1</sup> Data from the Global HPP Registry, sponsored by Alexion Pharmaceuticals, an observational, longitudinal, multinational, long-term study collecting data on HPP diagnosis, history, clinical course, symptoms (including multisystemic aspects of disease) and burden of illness from patients who have a diagnosis of HPP.<sup>1,5</sup> <sup>†</sup>Includes craniosynostosis, developmental delay, increased intracranial pressure and seizures.<sup>1</sup> <sup>‡</sup>Includes bone deformity, pseudofractures, recurrent and poorly healing fractures, rickets-like changes (by radiograph).<sup>1</sup> HPP, hypophosphatasia; QoL, quality of life.

1. Högler W, et al. *BMC Musculoskelet Disord*. 2019;20(1):80.
2. Dahir KM, et al. *Orphanet J Rare Dis*. 2022;17(1):277.
3. Rush ET, et al. *Orphanet J Rare Dis*. 2019;14(1):201.
4. Seefried L, et al. *J Bone Miner Res*. 2020;35(11):2171–2178.
5. Szabo SM, et al. *Orphanet J Rare Dis*. 2019;14(1):85.

The Alexion logo is a registered trademark of Alexion Pharmaceuticals, Inc.  
This material is intended for healthcare professionals only.

© 2025 Alexion Pharmaceuticals, Inc. All rights reserved.

GL/UNB-H/0019 | February 2025

**ALEXION**<sup>®</sup>  
AstraZeneca Rare Disease